Serious Adverse Events Consortium Expects Data On Genetic Variants Shortly
Executive Summary
Initial data generated by the Serious Adverse Events Consortium with regard to DNA variants associated with drug-related serious skin rash will be available at the end of 2008 or in January 2009, SAEC executive director Arthur Holden predicts
You may also be interested in...
BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development
BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.
BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development
BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor